These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 29451900

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IeM.
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A, Sarian LO, Ferracini AC, Costa LBE, Mazzola PG, de Angelo Andrade L, Derchain S.
    Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
    [Abstract] [Full Text] [Related]

  • 4. MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas.
    Eppich S, Kuhn C, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Gallwas J, Heidegger HH.
    Int J Mol Sci; 2020 Jun 25; 21(12):. PubMed ID: 32630554
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
    Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J.
    Eur J Gynaecol Oncol; 2015 Jun 25; 36(3):260-7. PubMed ID: 26189250
    [Abstract] [Full Text] [Related]

  • 6. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I, Seidal T.
    Int J Gynecol Cancer; 2011 Aug 25; 21(6):1024-31. PubMed ID: 21792012
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis.
    Liu G, Xu P, Fu Z, Hua X, Liu X, Li W, Zhang M, Wu J, Wen J, Xu J, Jia X.
    J Cell Biochem; 2017 Dec 25; 118(12):4517-4525. PubMed ID: 28466574
    [Abstract] [Full Text] [Related]

  • 8. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN, Lin MC, Tseng LH, Chiang YC, Lin LI, Lin YF, Huang HY, Kuo KT.
    Histopathology; 2015 Mar 25; 66(4):517-28. PubMed ID: 25195947
    [Abstract] [Full Text] [Related]

  • 9. Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.
    Matsuo Y, Tashiro H, Yanai H, Moriya T, Katabuchi H.
    Med Mol Morphol; 2015 Sep 25; 48(3):146-54. PubMed ID: 25398420
    [Abstract] [Full Text] [Related]

  • 10. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
    Khalique S, Naidoo K, Attygalle AD, Kriplani D, Daley F, Lowe A, Campbell J, Jones T, Hubank M, Fenwick K, Matthews N, Rust AG, Lord CJ, Banerjee S, Natrajan R.
    J Pathol Clin Res; 2018 Jul 25; 4(3):154-166. PubMed ID: 29659191
    [Abstract] [Full Text] [Related]

  • 11. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G, Gamallo C, Pérez-Gallego L, de Mora JC, Suárez A, Palacios J.
    Diagn Mol Pathol; 2001 Jun 25; 10(2):116-22. PubMed ID: 11385321
    [Abstract] [Full Text] [Related]

  • 12. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih IeM.
    Am J Surg Pathol; 2011 May 25; 35(5):625-32. PubMed ID: 21412130
    [Abstract] [Full Text] [Related]

  • 13. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
    Allo G, Bernardini MQ, Wu RC, Shih IeM, Kalloger S, Pollett A, Gilks CB, Clarke BA.
    Mod Pathol; 2014 Feb 25; 27(2):255-61. PubMed ID: 23887303
    [Abstract] [Full Text] [Related]

  • 14. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
    Liew PL, Fang CY, Lee YC, Lee YC, Chen CL, Chu JS.
    Diagn Pathol; 2016 Aug 03; 11(1):68. PubMed ID: 27488395
    [Abstract] [Full Text] [Related]

  • 15. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
    Choi JY, Han HH, Kim YT, Lee JH, Kim BG, Kang S, Cho NH.
    Yonsei Med J; 2017 Jan 03; 58(1):59-66. PubMed ID: 27873496
    [Abstract] [Full Text] [Related]

  • 16. Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.
    Briese J, Schulte HM, Sajin M, Bamberger C, Redlin K, Milde-Langosch K, Löning T, Bamberger AM.
    Virchows Arch; 2008 Jul 03; 453(1):89-96. PubMed ID: 18415123
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
    Hoang LN, Han G, McConechy M, Lau S, Chow C, Gilks CB, Huntsman DG, Köbel M, Lee CH.
    Histopathology; 2014 Mar 03; 64(4):585-96. PubMed ID: 24103020
    [Abstract] [Full Text] [Related]

  • 18. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
    Lowery WJ, Schildkraut JM, Akushevich L, Bentley R, Marks JR, Huntsman D, Berchuck A.
    Int J Gynecol Cancer; 2012 Jan 03; 22(1):9-14. PubMed ID: 22193641
    [Abstract] [Full Text] [Related]

  • 19. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF, Pizer ES, Ronnett BM, Kurman RJ.
    Hum Pathol; 1998 Jun 03; 29(6):551-8. PubMed ID: 9635673
    [Abstract] [Full Text] [Related]

  • 20. Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer.
    Beyer S, Chen F, Meister S, Czogalla B, Kolben TM, Hester A, Burges A, Trillsch F, Schmöckel E, Mayr D, Mayerhofer A, Mahner S, Jeschke U, Kolben T.
    Histochem Cell Biol; 2020 Aug 03; 154(2):189-195. PubMed ID: 32388637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.